Prenatal screening and diagnostic tests are essential laboratory and imaging procedures used to evaluate fetal health, assess the risk of chromosomal abnormalities, and confirm genetic conditions during pregnancy. This comprehensive technical guide explores sample types, testing methodologies, clinical applications, and practical considerations to help clinicians and laboratory professionals optimize prenatal care pathways.
Technical Overview
Prenatal testing encompasses two complementary categories of procedures: screening tests and diagnostic tests. Screening tests, including maternal serum analysis, fetal ultrasound assessment, and cell-free DNA (cfDNA) testing, are non-invasive methods that estimate the probability that a pregnancy is affected by a specific condition. They do not provide a definitive diagnosis but stratify patients into low-risk and high-risk groups, guiding decisions about further evaluation.
Diagnostic tests, by contrast, involve the direct analysis of fetal cells or tissues obtained through invasive procedures such as amniocentesis or chorionic villus sampling (CVS). These tests deliver definitive cytogenetic or molecular results and are considered the gold standard for confirming chromosomal aneuploidies, copy number variants, and single-gene disorders.
Key performance parameters for screening protocols include the detection rate (sensitivity), the false-positive rate (specificity), and the odds of an affected result given a positive screen (OAPR). Modern integrated screening pathways combine first-trimester and second-trimester markers to maximize detection while minimizing unnecessary invasive procedures, which carry a small but measurable procedurerelated pregnancy loss risk of approximately 0.1% to 0.3%.
Testing Samples
Maternal Blood
Maternal venous blood serves as the sample for all non-invasive screening modalities. Maternal serum is analyzed for placental and fetal proteins, while maternal plasma is processed to extract cell-free fetal DNA, which originates from placental trophoblasts and typically represents a fetal fraction of 4% to 30% after 10 weeks of gestation. A low fetal fraction (below 4%) may render cfDNA results uninterpretable and necessitates redraw or alternative screening.
Amniotic Fluid
Amniotic fluid is obtained via amniocentesis, typically performed between 15 and 20 weeks of gestation under continuous ultrasound guidance. The sample contains viable fetal cells sloughed from the fetal skin, gastrointestinal tract, and urogenital tract. Approximately 15 to 20 mL of fluid is aspirated, providing sufficient cellular material for karyotyping, chromosomal microarray analysis (CMA), fluorescence in situ hybridization (FISH), and molecular testing.
Chorionic Villi
Chorionic villus sampling, performed between 10 and 13 weeks of gestation, yields placental trophoblast tissue that is genetically representative of the fetus in the vast majority of cases. Villi may be collected transabdominally or transcervically. Because CVS can be executed earlier in pregnancy, it offers the advantage of earlier diagnostic confirmation, though it carries a small risk of confined placental mosaicism, which may require follow-up amniocentesis for clarification.
Fetal Cord Blood
Percutaneous umbilical cord blood sampling (cordocentesis or PUBS) is a third-trimester procedure reserved for specific indications such as rapid karyotyping, evaluation of fetal anemia, or assessment of suspected fetal infection. Direct access to fetal circulation allows real-time hematological analysis, including hemoglobin measurement and reticulocyte counts in cases of alloimmune hemolytic disease.
Testing Items
Prenatal testing panels are designed to detect a defined spectrum of fetal conditions, and the selection of analytes depends on gestational age, clinical history, and screening strategy:
- Chromosomal aneuploidies: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome aneuploidies such as Turner syndrome (45,X) and Klinefelter syndrome (47,XXY).
- Neural tube defects: elevated maternal serum alpha-fetoprotein (MSAFP) and detailed fetal ultrasound assessment for open spina bifida and anencephaly.
- Copy number variants (CNVs): submicroscopic deletions and duplications such as 22q11.2 deletion syndrome, detectable by chromosomal microarray analysis.
- Single-gene disorders: cystic fibrosis, sickle cell disease, thalassemia, Duchenne muscular dystrophy, and hemophilia, typically tested when parental carrier status or family history is established.
- Fetal structural anomalies: detailed anatomical survey by second-trimester ultrasound, including cardiac evaluation through fetal echocardiography.
- Additional assessments: fetal infection testing (CMV, toxoplasmosis), RhD genotyping in alloimmunized pregnancies, and fetal lung maturity testing in select late-gestation scenarios.
Testing Methods
Multiple laboratory methodologies are employed across the prenatal testing continuum, ranging from immunoassays to advanced genomic platforms:
- First-trimester combined screening: integrates nuchal translucency (NT) measurement by ultrasound, maternal serum pregnancy-associated plasma protein A (PAPP-A), and free beta-human chorionic gonadotropin (free β-hCG), achieving a trisomy 21 detection rate of approximately 82% to 87% at a 5% false-positive rate.
- Quadruple marker screen: performed at 15 to 22 weeks, measuring AFP, total hCG, unconjugated estriol (uE3), and inhibin A, with a detection rate of approximately 81% when combined with maternal age.
- Integrated and sequential screening: combines first-trimester and second-trimester serum markers with NT to improve detection rates up to 95% while maintaining a low false-positive rate.
- Non-invasive prenatal testing (NIPT): analyzes cell-free fetal DNA in maternal plasma using massively parallel sequencing or single nucleotide polymorphism (SNP)-based approaches. NIPT demonstrates detection rates exceeding 99% for trisomy 21 with false-positive rates below 0.1%, though positive results must be confirmed by diagnostic testing.
- G-banded karyotyping: conventional cytogenetic analysis of cultured amniocytes or chorionic villi, providing whole-genome resolution of approximately 5 to 10 Mb with a reporting turnaround of 7 to 14 days.
- Fluorescence in situ hybridization (FISH) and quantitative fluorescence PCR (QF-PCR): rapid interphase techniques targeting chromosomes 13, 18, 21, X, and Y, delivering preliminary results within 24 to 48 hours.
- Chromosomal microarray analysis (CMA): array comparative genomic hybridization (aCGH) or SNP arrays detecting CNVs at resolutions of 50 to 100 kb, recommended as a first-tier diagnostic test for pregnancies with structural anomalies identified on ultrasound.
- Multiplex ligation-dependent probe amplification (MLPA) and Sanger or next-generation sequencing (NGS): targeted molecular assays for known familial variants, with exome sequencing increasingly applied in fetuses with multiple anomalies of unknown etiology.
Applications
Prenatal screening and diagnostic testing are applied across diverse clinical scenarios to inform pregnancy management, prepare families, and enable timely interventions:
- Advanced maternal age: women aged 35 years or older at delivery have elevated aneuploidy risk and are offered enhanced screening or direct diagnostic testing.
- Positive or high-risk screening results: patients with abnormal combined, quad, or NIPT results are referred for genetic counseling and offered confirmatory amniocentesis or CVS.
- Fetal anomalies detected on ultrasound: structural findings such as increased nuchal translucency, cystic hygroma, cardiac defects, or growth restriction warrant CMA and, in selected cases, exome sequencing.
- Parental carrier status or family history: couples with known genetic conditions, balanced translocations, or previous affected offspring benefit from targeted molecular prenatal diagnosis.
- Assisted reproductive technology: pregnancies conceived through IVF, particularly those using preimplantation genetic testing, may undergo confirmatory prenatal diagnostic procedures.
- Pregnancy management planning: definitive diagnosis allows informed decision-making regarding continuation of pregnancy, delivery planning at equipped centers, in-utero therapy where available, and neonatal surgical preparedness.
FAQ
What is the fundamental difference between screening and diagnostic tests?
Screening tests are non-invasive risk assessments performed on maternal blood or by ultrasound; they estimate probability but cannot confirm a diagnosis. Diagnostic tests analyze fetal genetic material obtained through amniocentesis or CVS and provide definitive results with diagnostic accuracy exceeding 99%.
When should each type of test be performed during pregnancy?
NIPT can be performed from 10 weeks of gestation; first-trimester combined screening is optimally completed between 11 and 13 weeks 6 days; the quad screen is performed between 15 and 22 weeks; CVS is performed between 10 and 13 weeks; and amniocentesis is typically performed after 15 weeks of gestation.
Do invasive diagnostic procedures carry significant risk?
Modern amniocentesis and CVS are safe when performed by experienced operators under continuous ultrasound guidance. The procedurerelated miscarriage risk is approximately 0.1% to 0.3%, which should be weighed against the probability of the condition being investigated during individualized genetic counseling.
Does a positive screening result mean the fetus is affected?
No. A positive screen indicates elevated risk, not a diagnosis. Depending on the screening modality, most screen-positive pregnancies are unaffected, which is why all positive screening results should be confirmed with a diagnostic test before irreversible clinical decisions are made.
Can prenatal testing detect all genetic conditions?
No test detects every genetic disorder. Standard panels target common aneuploidies and selected CNVs, while single-gene testing requires knowledge of the specific familial variant. Patients should receive comprehensive pre-test and post-test counseling regarding the scope and limitations of each testing modality.